REG - Kanabo Group PLC - Patent Advancement

KanaboAnnouncement

15/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211215:nRSO6633Va&default-theme=true

RNS Number : 6633V  Kanabo Group PLC  15 December 2021

 

Kanabo Group Plc

 

('Kanabo' or 'the Company')

 

KANABO'S CBD BASED 'SMOKING CESSATION" FORMULA MOVES CLOSER TO FULL PATENT
APPROVAL

 

Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that
focuses on the distribution of cannabis-derived products for medical patients
and wellness CBD consumers, is pleased to announce that its unique CBD and
nicotine formula has advanced from Patent Cooperation Treaty (PCT) phase to
National Phase in the US, UK, and EU countries - the last phase before
becoming an internationally approved patent.

 

Highlights;

·    Kanabo's unique CBD and nicotine formula has advanced from PCT phase
to National Phase - the last phase before becoming an internationally approved
patent.

·    The formula can be used to treat nicotine and tobacco addiction, with
evidence suggesting the programme significantly reduces physical and
psychological nicotine withdrawal effects by an average of 70 per cent.

·    The formula is targeted at both the traditional smoking and
e-cigarettes markets which are expected to reach £50mil over the coming
years.

 

Avihu Tamir, CEO Kanabo, said, "Our unique patent pending CBD formulations and
controlled and consistent delivery device, the VapePod, represents an
excellent opportunity for governments to quickly end the reliance on tobacco
for millions of citizens worldwide. Our tests show a dramatic reduction in
nicotine consumption, whether in cigarettes or e-cigarettes, which can only be
good news for health services around the world."

 

Kanabo's unique, high potency CBD and nicotine and standalone CBD formulas,
delivered by their proprietary cartridges and VapePod, can be used to treat
nicotine and tobacco addiction, with evidence so far suggesting the programme
significantly reduces physical and psychological nicotine withdrawal effects.
The formula is targeted at both the traditional smoking and e-cigarettes
markets which are expected to reach £50mil over the coming years.

 

The application covers a unique new formula of specific naturally derived
terpenes to allow the application of a very consistent and reproducible, high
concentration of CBD throughout the life of the Kanabo cartridge. Initially,
CBD is combined with Nicotine, which is then reduced over several weeks until
there is zero Nicotine presence.

 

Tests with a handful of volunteers that participated in Kanabo's trial, have
presented an average reduction of 70 per cent in their cigarette consumption
and did not experience physical or psychological withdrawal effects.

 

As countries worldwide continue to seek measures to reduce tobacco smoking and
even ban the use of tobacco products*, Kanabo's new IP offers a novel and
effective way to reduce smoking and potentially complete withdrawal from
Nicotine and e-cigarette addiction.

 

 

For further information, please visit http://www.kanabogroup.com
(http://www.kanabogroup.com) or contact the following:

 Kanabo Group Plc
 Avihu Tamir, CEO                                       Via Vox Markets

 Peterhouse Capital Ltd
 Eran Zucker (Financial Adviser)                        Tel: +44 (0)20 7469 0930
 Lucy Williams / Charles Goodfellow (Corporate Broker)  Tel: +44 (0)20 7469 0930

 Vox Markets (Investor Relations)
 Kat Perez                                              KanaboGroup@voxmarkets.co.uk (mailto:KanaboGroup@voxmarkets.co.uk)

 

 

About Kanabo Group Plc

Kanabo Group Plc is a medical cannabis and R&D company currently selling a
range of wellness CBD Products across its Primary Markets and developing a
range of and Medical Cannabis Products. The company's core strategy is to
increase revenues from the sale of its Retail CBD Products in the wellness
sector and to grow the Kanabo brand through its marketing initiatives. Learn
more at https://www.voxmarkets.co.uk/listings/LON/KNB
(https://www.voxmarkets.co.uk/listings/LON/KNB)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFFIFVLSLIL